Episode Details

Back to Episodes
Incorporating AKT1 and PIK3CA Pathway Testing and Targeted Therapies in the Management of Advanced Endocrine-Resistant Breast Cancer

Incorporating AKT1 and PIK3CA Pathway Testing and Targeted Therapies in the Management of Advanced Endocrine-Resistant Breast Cancer

Episode 254 Published 12 hours ago
Description

Listen in to learn from Cristina Saura Manich, MD, PhD and Giampaolo Bianchini, MD about practical approaches to PI3K pathway testing, PI3K/AKT-targeted treatment options, and endocrine-based sequencing in metastatic breast cancer.

Presenters:

Cristina Saura Manich, MD, PhD
Head, Breast Cancer Unit
Medical Oncology Service
Vall d'Hebron University Hospital
Breast Cancer Program, Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Giampaolo Bianchini, MD
Associate Professor, Universita Vita-Salute San Raffaele
Head, Breast Cancer Group, Department of Medical Oncology
Head, Clinical Translational and Immunotherapy Research
IRCCS Ospedale San Raffaele
Milan, Italy

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Visit the program page for more content associated with this discussion.
https://bit.ly/4p6W8gP


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us